Duquesne Family Office - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.

Quarter-by-quarter ownership
Duquesne Family Office ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2022$2,241,296
+51.1%
58,9970.0%0.11%
+32.1%
Q3 2022$1,483,000
-17.3%
58,9970.0%0.08%
-35.4%
Q2 2022$1,793,000
-7.2%
58,9970.0%0.13%
+54.8%
Q1 2022$1,933,000
-82.0%
58,997
-85.5%
0.08%
-78.4%
Q4 2021$10,713,000
-84.7%
406,264
-41.5%
0.39%
-82.9%
Q3 2021$69,927,000
-22.5%
695,033
+9.1%
2.27%
+1.6%
Q2 2021$90,203,000
+20.6%
637,344
-15.0%
2.23%
+35.4%
Q1 2021$74,765,000
-19.3%
749,8970.0%1.65%
-33.9%
Q4 2020$92,702,000
+75.0%
749,897
+37.9%
2.50%
+62.4%
Q3 2020$52,987,000
-36.3%
543,901
+2.1%
1.54%
-39.5%
Q2 2020$83,140,000
+8.3%
532,878
+0.2%
2.54%
-18.3%
Q1 2020$76,771,000
-12.0%
531,878
+24.6%
3.11%
+21.7%
Q4 2019$87,234,000
+527.0%
426,719
+146.3%
2.56%
+372.6%
Q3 2019$13,913,000173,2850.54%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q3 2020
NameSharesValueWeighting ↓
CPMG Inc 3,023,349$285,253,00033.71%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 245,000$23,116,00017.80%
Prosight Management, LP 124,965$11,790,0005.94%
Cormorant Asset Management, LP 806,150$76,060,0004.37%
LBJ Family Wealth Advisors, Ltd. 44,096$3,710,0002.74%
MORGENS WATERFALL VINTIADIS & CO INC 34,350$3,241,0002.23%
Biondo Investment Advisors, LLC 73,090$6,896,0001.64%
P.A.W. CAPITAL CORP 15,000$1,415,0001.53%
EMERALD ADVISERS, LLC 387,369$36,548,0001.47%
SPHERA FUNDS MANAGEMENT LTD. 112,769$10,640,0001.46%
View complete list of REATA PHARMACEUTICALS INC shareholders